Effect of trimetazidine in the short-term treatment for dilated cardiomyopathy patients with heart failure
10.3760/cma.j.issn.1008-6315.2011.04.012
- VernacularTitle:曲美他嗪短期治疗原发性扩张型心肌病心力衰竭的疗效分析
- Author:
Zhenliang LIU
;
Kaiyi SHI
- Publication Type:Journal Article
- Keywords:
Trimetazidine;
Dilated cardiomyopathy;
Heart failure
- From:
Clinical Medicine of China
2011;27(4):374-377
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the clinical efficacy of trimetazidine in short-term treatment for dilated cardiomyopathy accompanied by heart failure. Methods Sixty seven cases of dilated cardiomyopathy patients with heart failure were recruited and divided into two groups randomly,the control group(n = 33) had conventional therapy and the treatment group (n = 34) had conventional therapy plus oral tid 20 mg trimetazidine administration for 3 months. Results The heart function improved significantly in both groups. The overall effective rate was significantly lower in the control group than the treatment group(69. 7% vs. 88.2%,P ＜ 0. 05). In the treatment group, before treating the left ventricular ejection fraction(LVEF), stroke volume (SV), cardiac output per minute (CO), 6 min walk test(6-MWT), were(28.7 ± 13. 6) %,(31.0 ± 8. 7) ml,(3. 10 ± 0. 49) L/min,(138.0 ± 30. 4) m respectively, and after treazing these indices were(38. 5 ± 9. 7) %,(48. 5 ± 6. 8) ml, (4. 90 ± 0. 98) L/min,(350. 0 ± 20. 4) m respectively, which increased significantly after treatment(Ps ＜0. 05). However,in the treatment group ,before treatment left ventricular. End-systolic dimension (LVESD), left ventricular end-diastolic dimension (LVEDD) and brain natriuretic peptide (BNP) were (68. 0 ± 8. 0)mm,(70. 0 ± 7. 8) mm,(669. 0 ± 71.4) μg/L respectively, whereas after treatment these indices were(59. 0 ± 6. 7) mm,(68.0 ± 7. 9) μg/L,(340. 0 ± 56. 0) μg/L respectively, which decreased significantly after treatment(Ps ＜ 0. 05). In the control group, before treatment LVEF, SV, CO, 6-M WT were(28. 5 ±13.9) %,(30. 0 ± 9. 9) ml,(3.00 ± 0. 48) L/min,(130. 0 ± 28. 6) m respectively, whereas after treating these indices were(34. 0 ± 8. 5) %,(34. 0±11.0) ml,(3. 90 ± 0. 56) L/min,(254. 0 ± 30. 0) m, respectively,which increased significantly after treatment(Ps ＜ 0. 05). While in the control group, before treatment LVESD,LVEDD and BNP were (67.0 ± 9. 0) mm, (70. 0 ± 8.0) mm,(666. 0 ± 70. 8) μg/L respectively, whereas after treatment these indices were(60. 0 ± 5. 5) mm,(66. 0 ± 5.7) mm,(350. 0 ± 55.3) μg/L respectively, which decreased significantly after treatment (Ps ＜ 0. 05). Moreever, the improvement of these indices in the treatment group were significantly higher than those in the control group (Ps ＜ 0. 05). Conclusion The additional administration of trimetazidine to conventional anti-failure treatment can significantly improve the heart function in patients with dilated cardiomyopathy,which is worth to be generalized clinically.
